1. Home
  2. BMI vs CELC Comparison

BMI vs CELC Comparison

Compare BMI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Badger Meter Inc.

BMI

Badger Meter Inc.

N/A

Current Price

$154.09

Market Cap

3.6B

Sector

Industrials

ML Signal

N/A

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$53.29

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BMI
CELC
Founded
1905
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.2B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
BMI
CELC
Price
$154.09
$53.29
Analyst Decision
Buy
Strong Buy
Analyst Count
10
13
Target Price
★ $165.75
$150.85
AVG Volume (30 Days)
505.9K
★ 920.9K
Earning Date
10-22-2026
11-05-2026
Dividend Yield
★ 1.14%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 3.19
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.09
$1,921.71
P/E Ratio
$48.50
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$112.09
$53.54
52 Week High
$186.76
$151.02

Technical Indicators

Market Signals
Indicator
BMI
CELC
Relative Strength Index (RSI) 54.23 30.06
Support Level $142.29 N/A
Resistance Level $154.15 $72.76
Average True Range (ATR) 6.61 4.24
MACD -1.17 -1.03
Stochastic Oscillator 17.83 0.16

Price Performance

Historical Comparison
BMI
CELC

About BMI Badger Meter Inc.

Badger Meter is a provider of water management solutions. The company's solutions encompass measurement and control hardware, connectivity and communication, data visualization and software. Badger Meter has global operations, with the vast majority of revenue derived from the US.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: